Massivemarkets

IRD

Opus Genetics, Inc. Common Stock

Nasdaq · usd

$3.28-0.19 (-5.45%)
As of 2:34:47 PM EDT on Oct 26, 2026 · 15-minute delayed

Opus Genetics, Inc. Common Stock (IRD) trades at $3.28 (-5.45%) as of 2:34:47 PM EDT on Oct 26, 2026, -29.73% over the past month. Market cap is $288.69M, with 6.0 days to cover in short interest.

Stock performance

How Opus Genetics, Inc. Common Stock (IRD) stock has performed from one day to one year, with its 52-week range.

-11.82%
-$0.44 over 1D
$3.31$3.44$3.56$3.694:40 AM10:30 AM11:50 AM1:10 PM2:30 PM$3.28
1D
-3.60%
1W
-12.43%
1M
-29.73%
YTD
+66.42%
1Y
+67.25%
52-wk range
$1.70 – $7.07

Key statistics

Today's trading snapshot for IRD: day range, open, previous close, volume and market cap.

Day range
$3.28 – $3.50
Open
$3.49
Prev close
$3.47
Volume
772.72K
Market cap
$288.69M
Shares out
82.65M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Opus Genetics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
29.29
P/B
-22.23
P/FCF
—
ROE
828.7%
ROA
-115.8%
Debt/Equity
-2.69
Div yield
0.00%

As of Oct 23, 2026

8-K filings

Material corporate events Opus Genetics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Executive officer departureOct 21, 2026

    Opus Genetics, Inc. (the "Company") and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the Company's Chief Scientific and Development Officer, effective as of October 19, 2026 (the "Separation Date").

  • Clinical trial resultsOct 15, 2026

    On October 15, 2026, Opus Genetics, Inc. issued a press release regarding the Company's October 14, 2026 presentations at the Retina in Rio 2026 conference. The presentations covered clinical data from Cohort 1 of the Company's ongoing Phase 1/2 clinical trial of OPGx-BEST1 and clinical data from the Company's ongoing Phase 1/2/3 clinical trial of OPGx-LCA5.

  • Clinical trial resultsSep 11, 2026

    On September 11, 2026, Opus Genetics, Inc. issued a revised version of the Company's data presentation ... announcing clinical data from Cohort 1 of the Company's ongoing Phase 1/2 clinical trial of OPGx-BEST1 in patients with BEST1-related retinal diseases.

  • Clinical trial resultsSep 9, 2026

    On September 9, 2026, the Company shared 3- and 6-month results from the low-dose Cohort 1 of BIRD-1, the Company's ongoing Phase 1/2 clinical trial of OPGx-BEST1 in patients with BEST1-related retinal diseases... Following treatment with OPGx-BEST1, all five participants demonstrated clinically meaningful improvement in visual function... Structural improvements were also observed across four participants.

  • Investor presentationJun 16, 2026

    management of Opus Genetics, Inc., a Delaware corporation (the "Company"), delivered a corporate presentation at its Virtual R&D Science Forum held on June 16, 2026. A webcast of the presentation is accessible through the investor relations section of the Company's website. The presentation is attached hereto as Exhibit 99.1

IRD short interest

How heavily IRD is shorted: shares short, days to cover and average daily volume.

Days to cover
6.0
Short interest
13.01M
Avg volume
2.15M

As of · reported to FINRA twice monthly.

IRD news

The latest news and headlines about Opus Genetics, Inc. Common Stock (IRD).

Frequently asked questions

What is the Opus Genetics, Inc. Common Stock (IRD) stock price today?

Opus Genetics, Inc. Common Stock (IRD) is trading at $3.28 (-5.45% on the day) as of 2:34:47 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Opus Genetics, Inc. Common Stock?

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders.

What is the short interest in IRD?

As of Sep 30, 2026, IRD has 13.01M shares short and 6.0 days to cover.

What exchange is IRD listed on?

Opus Genetics, Inc. Common Stock (IRD) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of IRD with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a IRD analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.